Relapsed/refractory mantle cell lymphoma patients significantly benefited from CAR T-cell therapy, with durable complete responses and manageable adverse events, according to new findings from the ZUMA-2 trial.
Two studies examine whether adding additional drugs to a standard chemotherapy regimen could improve outcomes for patients with subgroups of B-cell lymphoma.
Two new investigations show CAR T-cell therapy works for more than just model patients enrolled in clinical trials. Follow-up analysis and data show high-risk patients with comorbidities also responded to drug.
The overall program will cover important advances in the treatment of hematologic malignancies including mantle cell lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL) and more.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Learn why, when and how to refer your patients for this groundbreaking therapy.
Dr. Brian Hill discusses the one-year follow-up data of the ZUMA-1 trial to confirm anti-CD19 CAR T cell therapy’s stability of response.
This multicenter study shows that even with the relatively favorable outcomes of non-transplanted patients with mantle cell lymphoma in the modern era, the use of consolidation autologous stem cell transplant appears to further-improve progression-free and overall survival.
Like their predecessor generic drugs, biosimilars such as the just-approved postchemotherapy agent Zarxio could exert competitive pressure that lowers the cost of proprietary biological products.
Learn more about a Cleveland Clinic study led by oncologist Dr. Brian Hill, which links ethnicity-specific genes to chronic lymphocytic leukemia.